Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P08887
UPID:
IL6RA_HUMAN
Alternative names:
IL-6R 1; Membrane glycoprotein 80
Alternative UPACC:
P08887; A8KAE8; B2R6V4; Q16202; Q53EQ7; Q5FWG2; Q5VZ23
Background:
Interleukin-6 receptor subunit alpha, also known as IL-6R 1 or Membrane glycoprotein 80, plays a pivotal role in immune response and inflammation. It binds to IL6 with low affinity, requiring IL6ST for signal transduction. This receptor is involved in 'classic signaling', 'trans-signaling', and 'cluster signaling', regulating immune responses, acute-phase reactions, and hematopoiesis. Its soluble form, sIL6R, acts as an IL6 agonist, influencing chronic inflammatory diseases and tissue regeneration.
Therapeutic significance:
The involvement of Interleukin-6 receptor subunit alpha in Hyper-IgE recurrent infection syndrome 5 underscores its therapeutic potential. Targeting this receptor could lead to innovative treatments for immunologic disorders and chronic inflammatory diseases, highlighting the importance of understanding its functions and mechanisms.